Aislinn Antrim, Associate Editorial Director

Real-world ADA 2026 data shows bempedoic acid add-on lowers major heart risks in type 2 diabetes more than ezetimibe, despite smaller LDL drops.

High-dose semaglutide shows improved kidney markers and lowers inflammation in obesity without diabetes, suggesting benefits beyond weight loss.

Subgroup data show ofatumumab sharply cuts relapses, MRI lesions, and neurodamage markers in highly active relapsing MS vs teriflunomide.

Genetic analysis links low vitamin D and earlier menarche to higher AQP4-IgG NMOSD risk, reshaping prevention and sparking calls for diverse studies.

Phase 3 FENhance trial data show CNS-penetrant BTK inhibitor fenebrutinib cuts relapses and MRI lesions in relapsing MS.

New data show ublituximab boosts MS quality of life fast and may start in 1 infusion for relapsing multiple sclerosis.

New data show cladribine tablets deliver strong relapse control and reassuring safety in older adults with relapsing multiple sclerosis, including 65 years and older.

Frexalimab shows 3-year MRI and relapse control in relapsing multiple sclerosis with stable immunity and reassuring safety.

Amid the evolving landscape of MS treatments, there is an increasing emphasis on strategic approaches to early intervention and switching therapies.

ENHANCE trial data show ublituximab-xiiy can start with a single bioequivalent infusion, easing multiple sclerosis treatment initiation.

TrumpRx lists 600+ generic drugs with live cash prices, helping patients beat co-pays and sidestep PBMs amid rising drug prices.

Darren Triller, PharmD, walks through the relative ease and impact of each of the 5 ADAPT priority areas, makes the case for dashboard-driven population health management.

Securing executive buy-in, building multidisciplinary coalitions, and targeting inappropriate antiplatelet use are among the most critical steps in implementing antithrombotic stewardship programs.

FDA approval brings AstraZeneca’s Breztri Aerosphere triple asthma inhaler for patients 12 years and older, boosting lung function fast and simplifying daily control.

Anthony Blaszczyk, PhD, explains the intricacy of CGT manufacturing demands, best practices, and how USP is supporting developers.

Kyle Fischer, PharmD, explains navigating payer hurdles, supporting adherence, and improving coordination in ILD and PAH care.

Amy Seung outlines her priorities for leading HOPA through evolving therapies, workforce challenges, and expanding pharmacy roles.

Pharmacist Kyle Fischer, PharmD, APh, explains how antifibrotic therapy, drug interactions, and pharmacist–physician collaboration guide ILD care.

In a phase 2a trial, the oral NLRP3 inhibitor VTX3232 significantly reduced systemic and liver inflammation markers—including hsCRP and IL-6—independent of weight loss, suggesting a promising new approach to lowering cardiovascular risk in patients with obesity.

A phase 3 trial found that the oral PCSK9 inhibitor enlicitide significantly outperformed existing oral therapies in lowering LDL cholesterol.

Kelly Gable, PharmD, shares how empathy, presence, and practical guidance can transform patient experiences beyond the medication plan.

Alex Wolff, PharmD, BCOP, FHOPA, explains how patient populations, delivery models, and safety risks shape real-world implementation.

The trial's success offers the first robust evidence for targeted pharmacologic intervention in adolescent oHCM.

For decades, the medical community has operated under a reactive model for the most potent cholesterol-lowering drugs, largely reserving them for secondary prevention.

The findings emphasize that when it comes to the complex machinery of human blood pressure, more drug is not always better.

Gene and cell therapies are reshaping clinical workflows—and pharmacists are becoming essential guides in that shift.